Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%
01 Cellular Research Combines BPC-157, TB-500, GHK-Cu, and KPV for multi-pathway tissue repair and recovery research in a single vial
Plant-based ingredients (carrageenan), and alternative sweeteners for balanced wellness
Smoking People with lupus who smoke tend to have more active disease and discoid lupus involvement, which causes round disc-shaped sores and can lead to scarring
Peptide therapy should never be used as an excuse to ignore the foundations of tissue repair
These combinations lack clinical validation and require careful monitoring for adverse interactions